The AHA today urged the Centers for Medicare & Medicaid Services to suspend the pain-related questions in the Value-Based Purchasing Program while the agency works to address concerns the questions may inadvertently contribute to the opioid epidemic. The three questions are part of the Hospital Consumer Assessment of Healthcare Providers and Services. “The AHA agrees that the HCAHPS survey should inquire about pain management, that performance scores should be publicly reported, and that redesigned pain questions should eventually be reincorporated into the VBP program,” wrote Ashley Thompson, AHA senior vice president of public policy analysis and development. “However, we also want to ensure that the questions do not create pressure to prescribe opioids or other prescription painkillers or punish providers who, in their best judgment, choose not to prescribe them.”

Related News Articles

Headline
The Supreme Court April 29 ruled 7-2 in favor of the Department of Health and Human Services in a case that challenged how HHS applied Congress’ formula for…
Headline
The Food and Drug Administration published a notice from Amneal Pharmaceutical that said the company is recalling two lots of its Ropivacaine Hydrochloride…
Headline
The Food and Drug Administration has identified a Class I recall of Q’Apel Medical 072 Aspiration System after the company submitted three device event reports…
Headline
The Food and Drug Administration has issued alerts for issues with certain catheters made by BD and Conavi. BD identified an increase in material fatigue…
Headline
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at…
News
The Centers for Medicare & Medicaid Services April 7 released finalized payment rates for calendar year 2026 Medicare Advantage and Part D plans. Payments…